This Injectables Stock Rises 76% in 6 Months: What Is Behind the Sharp Rebound?
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
CMP Rs 2,946.90 (10 Sep 2026). 6-month return 76.06%. 52W range Rs 1,573.60 to Rs 3,042. Market cap Rs 49,901 Cr. Q1 FY27 PAT Rs 317 Cr, up 47%.
Quick Answer
Gland Pharma, a contract maker of sterile injectable medicines, is the injectables stock behind a return of approximately 76% in six months. The share climbed from a low of Rs 1,573.60 in March 2026 to near Rs 2,947 after profit nearly doubled in Q4 FY26 and rose 47% in Q1 FY27. The 5-year return is still negative and the share trades above the consensus analyst target.
This injectables stock has turned Rs 1 lakh into roughly Rs 1.76 lakh in just six months. One Hyderabad-based maker of sterile injectable medicines delivered a 6-month return of 76.06% as of 10 September 2026, ranking 13th in a screen of 101 large-cap and mid-cap NSE shares.
The company is Gland Pharma Ltd (NSE: GLAND), one of India’s largest contract makers of injectable drugs for global pharma companies. The Gland Pharma share price climbed from around Rs 1,674 in early March 2026 to Rs 2,946.90 on 10 September 2026, taking its market value to approximately Rs 49,901 crore. This injectables stock rallied after two strong quarterly results in a row.
Click Here – Get Free Investment Predictions
How Much Has This Injectables Stock Gained in 6 Months?
This injectables stock has gained approximately 76% in six months, placing it 13th out of 101 screened NSE stocks. The Gland Pharma share price closed at Rs 2,946.90 on 10 September 2026, down about 2.6% for the day from the previous close of Rs 3,026.20.
The injectables stock hit its 52-week low of Rs 1,573.60 on 16 March 2026 and a 52-week high of Rs 3,042 in early September. That is a bounce of roughly 87% from the bottom. Here is how the injectables stock has performed across time frames in our screen:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 2.46% | 62 |
| 6 Months | 76.06% | 13 |
| 1 Year | 50.40% | 31 |
| 3 Years | 78.88% | 54 |
| 5 Years | -19.55% | 100 |
Returns are simple price changes and are not annualised. The 5-year figure is the weak spot. Investors who bought in September 2021, close to the record high of Rs 4,350 touched in August 2021, are still sitting on a loss of about 19.55%, which ranks 100th out of 101 in the screen.
Profits fell from Rs 1,212 crore in FY22 to Rs 699 crore in FY25, and this injectables stock spent almost four years drifting lower. The 76% rally of the past six months is a recovery from that long slump, not a straight line of wealth creation. The 1-month return of 2.46% also shows the pace has cooled.
Why Did This Injectables Stock Rise 76% in 6 Months?
This injectables stock rose 76% because earnings turned sharply higher in two straight quarters, the US business accelerated, the CDMO pipeline expanded and the loss-making French unit moved closer to breakeven. Brokerage upgrades added fuel to the injectables stock move.
1. A Blockbuster Q4 FY26 Result in May
The first leg came on 18 May 2026, when this injectables stock jumped about 16% in a single session to Rs 2,170. Q4 FY26 revenue from operations rose around 22% year on year to Rs 1,743 crore, and net profit nearly doubled to about Rs 367 crore from Rs 186.5 crore.
The contract manufacturing (CDMO) segment contributed about 25% of revenue and grew approximately 65% during the quarter. Management also guided for 12% to 13% constant-currency revenue growth in FY27, which convinced investors the earnings slide was over.
2. Q1 FY27 Beat Expectations Across the Board
The second leg came on 11 August 2026, when the injectables stock surged as much as 12% intraday to Rs 2,989.25, its highest level since May 2022, after Q1 FY27 results beat estimates by around 5% to 9% on revenue, EBITDA and profit.
Reported revenue from operations rose 19.6% to Rs 1,800 crore, EBITDA grew about 33% to Rs 489 crore and net profit jumped 47% to Rs 317 crore. The reported EBITDA margin widened to 27.2% from 24.4% a year earlier.
3. The US Business Grew 32%
The US remains the largest market for this injectables stock. US revenue grew approximately 32% year on year to Rs 981 crore in Q1 FY27, helped by volume growth and new launches of complex injectables. Europe and other regulated markets grew about 11% to Rs 449 crore.
After the quarter, management raised its FY27 outlook to 15% to 16% constant-currency growth and set a goal of around 20% annual growth from FY28 onwards over four years.
4. New CDMO Contracts and GLP-1 Capacity
Gland Pharma signed a new sterile API supply arrangement and a manufacturing agreement for a sterile injectables portfolio expected to generate revenue from calendar year 2029. It is also scaling GLP-1 cartridge capacity from about 40 million units to 140 million, positioning the injectables stock for the weight-loss and diabetes drug wave as patents expire.
5. Cenexi Moving Toward Breakeven
The French subsidiary Cenexi was a drag on this injectables stock for two years. In Q1 FY27 it posted revenue of about EUR 48 million with a positive EBITDA margin, helped by better capacity use and workforce cuts. Management expects Cenexi revenue of around EUR 200 million in FY27, with margins improving to the mid-single digits.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Gland Pharma Financial Performance: Quarterly Trend
The quarterly numbers show why the market re-rated this injectables stock. Total income, including other income, has risen for five straight quarters, and profit has grown faster than revenue.
| Quarter | Total Income (Rs Cr) | EBITDA (Rs Cr) | Net Profit (Rs Cr) | Net Margin |
|---|---|---|---|---|
| Jun 2025 (Q1 FY26) | 1,563 | 425 | 215 | 14.3% |
| Sep 2025 (Q2 FY26) | 1,571 | 398 | 184 | 12.4% |
| Dec 2025 (Q3 FY26) | 1,759 | 498 | 261 | 16.4% |
| Mar 2026 (Q4 FY26) | 1,854 | 624 | 367 | 21.0% |
| Jun 2026 (Q1 FY27) | 1,862 | 551 | 317 | 17.6% |
For the full year FY26, total income rose about 16% to Rs 6,747 crore and net profit climbed around 47% to Rs 1,027 crore. EPS improved to Rs 62.28 from Rs 42.40, still below the FY22 peak of Rs 73.64.
The injectables stock has an almost debt-free balance sheet, with a debt-to-equity ratio of around 0.03. Operating cash flow was approximately Rs 1,031 crore in FY26 against capital spending of about Rs 494 crore, so the injectables stock funds its expansion from internal cash.
Is This Injectables Stock Overvalued After the Rally?
This injectables stock is not extreme on valuation, but it is no longer undervalued either. The injectables stock trades at a PE of approximately 44.2 against an industry PE of about 38.3, a premium of roughly 15%.
| Metric | Gland Pharma | Comment |
|---|---|---|
| PE Ratio (TTM) | 44.20 | Above industry PE of 38.26 |
| Price to Book | 4.82 | Book value Rs 627.88 per share |
| ROE | 9.92% | Still below FY22 levels |
| Debt to Equity | 0.03 | Nearly debt-free |
| Dividend Yield | 0.66% | Rs 20 per share for FY26 |
The low ROE of around 9.92% is the main reason some analysts remain cautious. The large cash pile and the Cenexi acquisition have diluted returns. If Cenexi margins improve as guided, ROE should rise, but that is still a forecast.
Injectables Stock Shareholding: Fosun Sale and Institutional Demand
Chinese promoter Fosun Pharma held about 51.83% for most of the past year before trimming to 51.77% in June 2026. FII holding climbed to 8.74% in June 2026 from 7.29% in March, while domestic institutions eased to 30.44% from 33.36%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Sep 2025 | 51.83% | 7.90% | 32.63% | 7.63% |
| Dec 2025 | 51.83% | 7.58% | 32.99% | 7.62% |
| Mar 2026 | 51.83% | 7.29% | 33.36% | 7.52% |
| Jun 2026 | 51.77% | 8.74% | 30.44% | 9.06% |
In the first week of September 2026, Fosun sold a large block of shares at around Rs 2,827 each, worth roughly Rs 2,100 crore to Rs 2,800 crore depending on the report. Large domestic mutual funds and insurers bought the shares. Reports put Fosun’s post-deal holding at around 46% to 47%, and the formal filing is still awaited.
A promoter selling into strength can weigh on sentiment, but strong demand from domestic funds at close to market price suggests institutions still back the injectables stock story.
Key Risks for This Injectables Stock
The rally has priced in a lot of good news. Investors should weigh these risks before chasing the injectables stock at current levels:
US pricing and regulatory risk: The US contributes more than half of revenue. Price erosion in generic injectables or any adverse USFDA inspection outcome could hurt growth quickly.
Promoter supply overhang: Fosun sold sizable stakes in 2024 and again in September 2026. Further sales could cap upside for the Gland Pharma share price.
Cenexi execution: The French unit is only just EBITDA positive. Any slip in its turnaround would pull consolidated margins lower.
Valuation and targets: The injectables stock already trades above the median analyst target, and several brokerages have ratings below the current price. That limits the margin of safety.
Weak long-term record: Despite the rally, the injectables stock is still about 32% below its 2021 record high, a reminder of how long a derating can last.
Download the Univest iOS App or Univest Android App to track the Gland Pharma share price live
Gland Pharma Share: Analyst View
Analysts are split on the injectables stock after the rally. A foreign brokerage upgraded the share to Buy after Q1 FY27, arguing that its key challenges are largely behind it, with US growth, new CDMO wins and in-licensed products as drivers. Another foreign brokerage retains a Sell rating.
Gland Pharma Share Price Target
The highest Gland Pharma share price target after the Q1 results is Rs 3,350, set by a foreign brokerage, implying about 14% upside from Rs 2,946.90. Two other brokerages have targets near Rs 3,330, while a domestic brokerage has a Buy call with a target of Rs 3,080 based on 30 times forward earnings.
At the other end, one foreign brokerage has a Sell rating with a Gland Pharma share price target of Rs 2,125, and the lowest target is Rs 1,940 from a domestic brokerage. The consensus target of approximately Rs 2,673 sits below the current Gland Pharma share price, which shows much of the injectables stock recovery is already priced in.
On the chart, the 52-week high of Rs 3,042 is the first level to watch on the upside, while the Rs 2,827 block deal price may act as a near-term support zone.
Conclusion
This injectables stock has staged one of the sharpest recoveries in the mid-cap pharma space, rising 76% in six months on the back of two strong results, 32% US growth, fresh CDMO contracts and a narrowing Cenexi loss. Profit grew 47% in FY26 and again in Q1 FY27.
The flip side is clear. The injectables stock is still below its 2021 peak, the 5-year return is negative, valuation is above the sector and the promoter is selling. Investors tracking this injectables stock should follow quarterly US growth and Cenexi margins closely rather than extrapolate the recent run.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which injectables stock rose 76% in 6 months?
Ans. Gland Pharma (NSE: GLAND) is the injectables stock that gained approximately 76.06% over six months as of 10 September 2026. This injectables stock ranked 13th among 101 large-cap and mid-cap NSE stocks screened for this analysis.
Why did Gland Pharma share price rise so much?
Ans. The rally came from two strong quarters, with Q4 FY26 profit nearly doubling and Q1 FY27 profit rising 47%. US revenue grew 32%, new CDMO contracts were signed and the Cenexi unit turned EBITDA positive.
What were Gland Pharma Q1 FY27 results?
Ans. Gland Pharma reported Q1 FY27 revenue from operations of about Rs 1,800 crore, up 19.6% year on year. Net profit rose 47% to Rs 317 crore and the EBITDA margin expanded to 27.2% from 24.4%.
What is the 52-week high and low of Gland Pharma?
Ans. The injectables stock has a 52-week high of Rs 3,042 and a 52-week low of Rs 1,573.60, hit on 16 March 2026. Gland Pharma closed at Rs 2,946.90 on 10 September 2026.
Why is the 5-year return of Gland Pharma negative?
Ans. The injectables stock peaked at around Rs 4,350 in August 2021 and then fell for years as profit dropped from Rs 1,212 crore in FY22 to Rs 699 crore in FY25. Even after the recent rally, the 5-year return is approximately -19.55%.
Did Fosun sell its stake in Gland Pharma?
Ans. Yes, promoter Fosun Pharma sold a large block at around Rs 2,827 per share in early September 2026. Domestic mutual funds and insurers were the main buyers, and reports put Fosun’s remaining stake at around 46% to 47%.
What is the Gland Pharma share price target?
Ans. Post-Q1 targets range from Rs 1,940 to Rs 3,350, with a consensus near Rs 2,673. The highest target implies about 14% upside from Rs 2,946.90, but targets are estimates and not guaranteed.
Should I invest in this injectables stock after a 76% rally?
Ans. Much of the recovery is already priced in, with the injectables stock above the consensus target and a promoter stake sale adding supply. Staggered buying, a clear stop loss and consulting a SEBI-registered advisor are sensible steps.
